EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphoma, gastrointestinal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor
• Hypereosinophilic Syndrome
• Myelodysplastic Myeloproliferative Neoplasms
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Glivec (imatinib)

Snippet

Status: Authorised. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Gastrointestinal Stromal Tumors;Dermatofibrosarcoma;Myelodysplastic-Myeloproliferative Diseases;Leukemia, Myelogenous, Chronic, BCR-ABL Positive;Hypereosinophilic Syndrome. MAH: Novartis Europharm Limited. Decision date: 16/10/2025